Way back in 2009 I did an I interview with Rosetta and its nice to see that the test is receiving more use and approval to locate cancer of the unknown in the diagnostic processes of lung cancer, in other words did the patient really have lung cancer or was it another cancer that travelled there and this test identifies that fact so the right treatments can be given.  BD

Rosetta Genomics Interview – microRNA for Diagnosing Lung Cancer Tumors

PHILADELPHIA and REHOVOT, Israel, May 20, 2013 -- PHILADELPHIA and REHOVOT, Israel, May 20, 2013 /PRNewswire/ -- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that the Company has executed a credentialing agreement with Prime Health Services, Inc. (Prime Health), a managed care company that offers a full spectrum of services, including a Preferred Provider Organization (PPO), for the inclusion of Rosetta Genomics' miRview® mets2 test in Prime Health's covered products and services.



Post a Comment